Drug Trial Radar · NCT06618001
A Study of JNJ-89853413 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms
Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
64
Actual
Start
Jan 14, 2025
Primary completion
Sep 1, 2026
Study completion Sep 1, 2026
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Oct 1, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of Part 1 (Dose Escalation) of the study is to assess the safety and tolerability, and to identify the recommended Phase 2 dose\[s\] (RP2D\[s\]) in participants with relapsed or refractory (R/R) acute myeloid leukemia (AML) (that is a type of blood cancer that has come back after treatment/or has stopped responding to treatment) or R/R higher-risk type of myelodysplastic neoplasms (MDS, type of blood cancer). The purpose of Part 2 (Cohort Expansion) is to further assess the safety, tolerability and efficacy in participants with R/R AML or higher-risk types of MDS.
Conditions
- Leukemia, Myeloid, Acute
- Myelodysplastic Neoplasms
Interventions
JNJ-89853413Drug
JNJ-89853413 will be administered.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Adverse events (AEs) by SeverityTime frame: From screening untill 30 days after last dose of study drug (that is approximately 2.5 years)
- Part 1: Number of Participants with Dose-Limiting Toxicity (DLTs)Time frame: 14 days
Locations
9 sites in 3 countries. Site status is shown where the registry gives one.
Arthur J E Child Comprehensive Cancer Centre
Calgary, Alberta, Canada
Vancouver General Hospital
Vancouver, British Columbia, Canada
Princess Margaret Hospital
Toronto, Ontario, Canada
Hosp Clinic de Barcelona
Barcelona, Spain
Hosp Univ Fund Jimenez Diaz
Madrid, Spain
Clinica Univ. de Navarra
Pamplona, Spain
Addenbrookes Hospital
Cambridge, United Kingdom
University College London Hospitals
London, United Kingdom
The Christie NHS Foundation Trust Christie Hospital
Manchester, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.